L26/O-064 Diagnosis and fertility aspects of POI
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von R. Anderson.
Abstract (Originalsprache)
ESHRE published an evidence based guideline on the diagnosis and management of women with premature ovarian insufficiency (POI) in 2015, and this has recently been updated. In the current version, published in 2025, the guideline was jointly developed by ESHRE, ASRM, CreWhirl and the International Menopause Society, giving it global relevance. Much of the guideline was comprehensively rewritten, and based on 40 PICO questions with 145 recommendations. This presentation is on behalf of the Guideline Deveopment Group. The diagnosis of POI remains based on the clinical presentation of irregular menstrual cycles with amenorrhoea, supported by laboratory confirmation based on measurement of FSH. In an important change from the 2015 guideline, an elevated FSH over 25 IU/L on a single occasion is sufficient to make the diagnosis. Serum estradiol (E2) should also be measured in the same sample to ensure that E2 is not high, and thus potentially suppressing FSH. No robust cut-off value for E2 is given, but it is noted that values of < 200pmol/l are generally accepted to be consistent with hypoestrogenism. The potential value of measurement of AMH is also reviewed. As a more proximate marker of the pool of non-growing and smaller growing follicles in the ovary, it has potential attractions compared to FSH and E2, and it is clear that AMH is very low in many women with POI. However there is very limited evidence of its value as a diagnostic test compared to FSH, and at present the recommendation is that AMH should not be used as the primary diagnostic test for POI, but that testing may be useful to confirm the diagnosis of POI where FSH results are inconclusive, with AMH results needing to be interpreted within the clinical context. Similarly, it is recommended that AMH testing is not used to predict POI due to insufficient evidence of accuracy. The guideline provides a flow-chart to guide further testing to assess the aetiology of POI. In many cases the aetiology is iatrogenic, from surgery or from administration of gonadotoxic treatments including chemotherapy and radiotherapy. In other cases, genetic testing should be performed, including a karyotype and testing from FMR1 (fragile X) mutations, with broader genetic testing based on availability. Testing for autoimmune aetiologies should include testing for 21 hydroxylase antibodies, to identify women with or at risk of Addisson’s disease. Testing for thyroid function is recommended, but if that is normal, testing for anti-thyroid antibodies is not due to their high prevalence in women without POI. It remains the case that for women with established POI, the chance of natural conception is low at approximately 5%. However in younger women with more recent onset of POI, the pregnancy rate may reach 15%. The only established effective treatment is through oocyte donation, Sisters or other close relatives may be suitable donors, but should be informed of the potential for shared genetic risk. While there are a range of novel approaches to increase the changes of conception in women with POI, based on surgical, platelet/stem cell and pharmacological based procedures and treatments, none have sufficient evidence for their efficacy to be yet recommended.
Zitieren
APA
Anderson, R. (2026). L26/O-064 Diagnosis and fertility aspects of POI. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.064
Vancouver
Anderson R. L26/O-064 Diagnosis and fertility aspects of POI. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.064
BibTeX
@article{Anderson2026,
author = {Anderson, R.},
title = {L26/O-064 Diagnosis and fertility aspects of POI},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.064}
}
EUVIMED